FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

GLP-1 drugs, including Wegovy, Zepbound, and Foundayo, help patients lose weight by mimicking a hormone that makes the body ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

European equities traded in the US as American depositary receipts were heading lower late Friday morning, declining 0.89% to 1,913.67 on the S&P Europe Select ADR Index, which is ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.

Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...

Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...